China-based Sino Biological, Inc. has concluded the acquisition of Canadian biotechnology company SignalChem Biotech Inc. (SCB). Sino Biological has acquired 100% of SCB shares in a deal valued at $48 million, inclusive of all assets, assumed indebtedness, and net of cash deposits.  

SignalChem Biotech Inc. is renowned for its specialised bioactive enzymes, including kinases, proteases, phosphatases, ubiquitin and epigenetic enzymes. Over the past two decades, SCB has established proprietary production and quality control platforms, setting industry standards for the development and production of high-quality bioactive enzyme proteins to support scientists from basic research through drug discovery and development. Now operating as a wholly-owned subsidiary of Sino Biological, SCB will bring exclusive expertise in enzyme production to the company’s existing technology platforms.

The strategic synergy between Sino Biological and SignalChem enables the provision of a broader range of products and research services, supporting the wider life sciences community and facilitating the discovery and development of novel treatments, vaccines and diagnostic platforms.